共 1038 条
[11]
Chiorazzi M(2017)Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma N Engl J Med 377 1250-1260
[12]
Giltnane JM(2014)Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study Blood. 123 2944-2952
[13]
Hurt EM(2013)Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial Lancet. 381 1203-1210
[14]
Zhao H(2018)Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study Leukemia & lymphoma 59 896-903
[15]
Averett L(2012)The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines Blood Cells Mol Dis 48 68-75
[16]
Henrickson S(2018)Genomic landscape and prognostic analysis of mantle cell lymphoma Cancer Gene Ther 25 129-140
[17]
Yang L(2019)Mutation profiling of malignant lymphoma by next-generation sequencing of circulating cell-free DNA J Cancer 10 323-331
[18]
Powell J(2019)Advances in molecular biology and targeted therapy of mantle cell lymphoma Int J Mol Sci 20 4417-38
[19]
Wilson WH(2005)Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL network Br J Haematol 131 29-813
[20]
Jaffe ES(2017)Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management Am J Hematol 92 806-1791